Dexcom CGM Use and Satisfaction in a Diverse Gestational Diabetes Cohort—Insights Into Glycemic Management and Patient Experiences

Introduction and Objective: Gestational Diabetes Mellitus (GDM) is increasingly prevalent, with racial and ethnic disparities influenced by social determinants of health. While CGM can improve outcomes, its use across diverse populations is underexplored. We studied GDM management and CGM satisfaction in a diverse cohort to address this gap. Methods: Women receiving care at a Southern US medical center wore Dexcom G6 real-time CGM from GDM diagnosis until delivery. Participants completed the CGM Satisfaction Survey one week before delivery, which assessed perceived benefits of CGM use and identified areas where additional support could help optimize CGM use. Participant characteristics, glucose metrics, and satisfaction were analyzed by race and other subgroups. Results: Sample included 78 women (mean ± SD; age 33 ± 5 years; 31% Black (BW), 4% other, 65% White (WW)). Participants had high CGM wear (89% ± 15) and reported high satisfaction with CGM. Key perceived benefits included “Teaches me how eating affects blood sugar” and “Makes it clearer how some everyday habits affect blood sugar.” BW had higher pregestational BMI compared to WW (40 ± 7 vs 36 ± 9 kg/m2). During pregnancy, BW exhibited lower TIR 63-140mg/dL (81% ± 13 vs 90% ± 7) and higher mean glucose (117 ± 12 vs 106 ± 8 mg/dL) than WW (all p<0.05). Despite glycemic differences, both groups had high CGM wear and reported similar high satisfaction with CGM. Additional subgroup analyses and open response themes revealed nuanced user experiences, varying by age (≥35 vs <35 years) and race between women using insulin vs no insulin. Conclusion: Women with GDM showed high engagement and satisfaction with Dexcom CGM, underscoring its potential to support diabetes management during pregnancy. Differences in glycemic outcomes and experiences highlight the need for tailored strategies to optimize CGM benefits across diverse populations and improve health equity in GDM care. Disclosure: M.A. Crawford: Employee; Dexcom, Inc. A.M. Spangenberg: Employee; Dexcom, Inc. K.E. Elkind-Hirsch: Other Relationship; Dexcom, Inc. Research Support; Dexcom, Inc. Advisory Panel; Lilly USA LLC. Research Support; Novo Nordisk A/S. Advisory Panel; Novo Nordisk A/S. H. Singh: Employee; Dexcom, Inc.